Document is current
Any future updates will be listed below
-
Authors
Stolz, Myriam https://orcid.org/0009-0001-9322-3312
Farr, Alex https://orcid.org/0000-0002-1882-787X
Tendl-Schulz, Kristina A. https://orcid.org/0000-0003-3288-8959
Frommlet, Florian https://orcid.org/0000-0003-4104-1768
Reckendorfer, Helga
Koperek, Oskar https://orcid.org/0000-0002-0191-8126
Neudert, Barbara
Marhold, Maximilian https://orcid.org/0000-0001-8439-3312
Heber, Ulrike https://orcid.org/0009-0004-4486-9442
Exner, Ruth https://orcid.org/0000-0002-1168-1310
Singer, Christian F. https://orcid.org/0000-0003-1294-0027
Bartsch, Rupert https://orcid.org/0000-0002-4384-6917
Bago-Horvath, Zsuzsanna https://orcid.org/0000-0002-8555-7806
-
Funding
Funding for this research was provided by:
Vienna Science and Technology Fund (LS20-065)
Magistrat der Stadt Wien (19018)
Roche Deutschland
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 6 May 2025
Revised: 14 July 2025
Accepted: 20 July 2025
First Online: 5 August 2025
Declarations
:
: This single-center retrospective study was approved by the Institutional Review Board of the Medical University of Vienna (protocol number: 1723/2019). Informed consent was obtained from all the patients.
: AF has received honoraria for lectures or advisory board participations from Schuelke, Pierre Fabre, BioNTech, Avodes, Exeltis, Dr. Kade, Medinova, as well as copyright claims from Medinova and a non-restricted grant from Roche Diagnostics GmbH; KTS has received honoraria for lectures or advisory board participation from Roche as well as travel support from Roche, Novartis, and Merck Sharp & Dohme GmbH (MSD); CFS reports grants, travel grants, speaker honoraria, and unrestricted grants from Amgen, AstraZeneca, Novartis, Gilead, Seagen, and MSD; ZBH reports lecture honoraria and advisory boards from MSD, AstraZeneca, Gilead, Stemline, and Daiichi Sankyo; all other authors declare that there are no financial or non-financial competing interests to declare.
